1. 1996-2006 Cycle times decreased in larger but not smaller, companies
APRIL 2007
SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS

2. Chapter 6
Cycle Times
Figure 6.2
Cycle times are decreased in larger but not smaller, companies
Key message
Based on a 3-year moving average, the Major companies represented have predominantly maintained shorter development times than the industry as a whole.
Methodology
Industry data: The data is displayed as a 3-year moving average (although the data point for 2006 includes data from 2005 and 2006 only). Development times have been calculated for 293 (74%) of the 398 New Molecular Entities (NMEs) that were first marketed in the period 1st January 1995 to 31st December NMEs with development times exceeding 25 years and all vaccines were excluded from this analysis.
Data for Major companies: These data, representing 139 NMEs, are displayed as a 3-year moving average (although the data point for 2006 includes data from 2005 and 2006 only). Note that the activities of companies that now form part of a larger company, due to merger and acquisition activities, have been attributed to the company group as it existed in 2006.
Key Definitions
New Molecular Entity (NME): A new chemical entity or biological (including products of biotechnology) that has not been previously available for therapeutic use in man and are destined to be made available as a ‘prescription only medicine’, to be used for the cure, alleviation, treatment, prevention or in vivo diagnosis of diseases in man. Vaccines, new salts, pro drugs, metabolites and esters of existing compounds and certain biological compounds (e.g. antigens) are not classified as NMEs. Combination products are excluded from the list unless one or more of the constituents of the combination product has never been previously available.
Development time: Time taken from compound code assigned to first world launch
CMR International Performance Metrics Programme / Source
Annual Survey of New Molecular Entity First Launches / New Medicine Launches 2006 A complete guide to New Molecular Entities (NMEs) launched world-wide.
* The development time data point for 2006 includes data from 2005 and 2006 only
Major companies are defined as those spending ≥US$ 1.8 billion in 2006 on ethical pharmaceutical R&D.
SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS

3. Terms of Use and Disclaimer
The materials contained in these slides may be used for your own use in presenting at conferences and meetings or for inclusion in reports provided that you acknowledge the source of the materials and include the following statement: “2008 © Thomson Reuters. Some of the materials and/or data in this [report, presentation, paper etc] are reproduced under a license from Thomson Reuters. You may not copy or re-distribute these materials in whole or in part without the written consent of Thomson Reuters”.
Charts, graphs, and illustrations contained in these slides may not be decompiled, reverse engineered, or disassembled.
The copyright and other intellectual property rights in these slides is owned by Thomson Reuters or its licensors. Except for the license set out in these Terms of Use, Thomson Reuters neither assigns any rights nor grants any licenses or rights in respect of these slides to you and any use of these slides other than in accordance with these Terms of Use is subject to Thomson Reuters’ prior written consent. For additional permissions, please contact: [contact ]
THOMSON REUTERS MAKES NO WARRANTY OR REPRESENTATION AS TO THE ACCURACY, COMPLETENESS OR CORRECTNESS OF ANY MATERIALS CONTAINED WITHIN THESE SLIDES OR THAT ALL ERRORS IN THE SLIDES OR THE MATERIALS CONTAINED WITHIN THESE SLIDES WILL BE CORRECTED.
THOMSON REUTERS IS AN INFORMATION PROVIDER AND DOES NOT PROVIDE LEGAL, FINANCIAL OR OTHER PROFESSIONAL ADVICE. THE MATERIALS CONTAINED IN THESE SLIDES ARE FOR GENERAL INFORMATION PURPOSES ONLY, ARE NOT INTENDED TO CONSTITUTE LEGAL OR OTHER PROFESSIONAL ADVICE, AND SHOULD NOT BE RELIED ON OR TREATED AS A SUBSTITUTE FOR SPECIFIC ADVICE RELEVANT TO PARTICULAR CIRCUMSTANCES. THOMSON REUTERS SHALL NOT BE LIABLE FOR ANY LOSS THAT MAY ARISE FROM ANY RELIANCE BY YOU, YOUR EMPLOYER OR CLIENT, OR ANY OTHER THIRD PARTY, ON THE MATERIALS CONTAINED IN THESE SLIDES.
THOMSON REUTERS WILL NOT BE LIABLE IN CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE FOR ANY INDIRECT, SPECIAL, PUNITIVE OR CONSEQUENTIAL LOSS OR DAMAGE ARISING OUT OF OR IN CONNECTION WITH THESE TERMS OF USE OR YOUR USE OF THE SLIDES, HOWEVER SUCH INDIRECT LOSS OR DAMAGE MAY ARISE.
You shall not assign, sub-licence or delegate any of your rights or obligations under these Terms of Use without the prior written consent of Thomson Reuters; any assignment, sub-licensing or delegation in breach of these Terms of Use shall be null and void. If any provision of these Terms of Use are determined to be illegal or unenforceable by any court of competent jurisdiction it shall be deemed to have been deleted without affecting the remaining provisions. These Terms of Use will be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania. You hereby irrevocably submit to the exclusive jurisdiction of the federal and state courts located in Philadelphia, PA, USA.